Percutaneous Coronary Intervention of Saphenous Vein Graft [Coronary Artery Disease]

Conclusions— SVG PCI is associated with a considerably higher risk of 2-year adverse ischemic events, with HPR conferring similar risk in SVG and non-SVG PCI. More potent and longer antiplatelet therapy may be beneficial for patients undergoing SVG PCI. Clinical Trial Registration— URL: http://www.clinicaltrials.gov. Unique identifier: NCT00638794.

http://circinterventions.ahajournals.org/cgi/content/short/10/5/e004953?rss=1

Source: Circulation: Cardiovascular Interventions - May 11, 2017 Category: Cardiology Authors: Redfors, B., Genereux, P., Witzenbichler, B., McAndrew, T., Diamond, J., Huang, X., Maehara, A., Weisz, G., Mehran, R., Kirtane, A. J., Stone, G. W. Tags: Percutaneous Coronary Intervention, Stent Coronary Artery Disease Source Type: research